ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
The company is assessing the situation and simultaneously undertaking all the requisite action
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Subscribe To Our Newsletter & Stay Updated